229 related articles for article (PubMed ID: 9352699)
1. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
4. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
Abrams P; Schulman CC; Vaage S
Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
[TBL] [Abstract][Full Text] [Related]
5. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
[TBL] [Abstract][Full Text] [Related]
6. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
[TBL] [Abstract][Full Text] [Related]
7. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
[TBL] [Abstract][Full Text] [Related]
8. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
[TBL] [Abstract][Full Text] [Related]
9. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).
Abrams P; Speakman M; Stott M; Arkell D; Pocock R
Br J Urol; 1997 Oct; 80(4):587-96. PubMed ID: 9352698
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
11. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
Tsujii T
Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
[TBL] [Abstract][Full Text] [Related]
13. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
Lee E; Lee C
Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
[TBL] [Abstract][Full Text] [Related]
14. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
Dunn CJ; Matheson A; Faulds DM
Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
[TBL] [Abstract][Full Text] [Related]
15. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; McTavish D
Drugs; 1996 Dec; 52(6):883-98. PubMed ID: 8957159
[TBL] [Abstract][Full Text] [Related]
16. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial.
Lapitan MC; Acepcion V; Mangubat J
J Int Med Res; 2005; 33(5):562-73. PubMed ID: 16222890
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
18. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI; Fitton A; McTavish D
Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
[TBL] [Abstract][Full Text] [Related]
19. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
Eur Urol; 1999 Dec; 36(6):609-20. PubMed ID: 10559616
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
